The TheraBionic P1 device is being evaluated for treatment efficacy of metastatic pancreatic cancer in combination with gemcitabine and nab-paclitaxel therapies. Clinical trials are underway in Michigan and North Carolina. Both clinical trials are recruiting adult participants (18 years and older) who meet eligibility criteria.